Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — FY2016 Q3 Earnings Presentation

36 slides from Daiichi Sankyo's earnings presentation, Jan 31, 2017

  1. Slide 1: Top Management Presentation: Financial Results for FY2016 Q3

    Top Management Presentation Financial Results for FY2016 Q3 (April 1 – December 31, 2016) DAIICHI SANKYO CO., LTD George Nakayama President and CEO January 31, 2017

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa

  3. Slide 3: Agenda

    Agenda  FY2016 Q3 Financial Results  FY2016 Revised Consolidated Forecast  Management Updates  Grow Edoxaban  Maximize Sales Potential of Injectafer  R&D Updates  Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma  ADC Franchise Enhancement 2

  4. Slide 4: FY2016 Q3 Financial Results

    FY2016 Q3 Financial Results 3

  5. Slide 5: Overview of FY2016 Q3 Results

    Overview of FY2016 Q3 Results (JPY Bn) FY2015 Q3 YTD FY2016 Q3 YTD YoY Results Results -3.2% Revenue 758.6 734.4 -24.2 Cost of Sales 237.7 241.7 +4.0 SG&A Expenses 232.3 220.5 -11.8 R&D Expenses 138.1 143.5 +5.4 -14.4% Operating Profit 150.4 128.7 -21.7 Profit before Tax 145.4 132.4 -13.0 -20.4% Pro

  6. Slide 6: Revenue

    Revenue Decreased by 24.2 Bn JPY (Increased by 16.6 Bn JPY excl. forex impact) (JPY Bn) FY2015 Results 758.6 Japan Positive : Lixiana +8.3 Tenelia +7.8 Japan Nexium +5.5 Inavir +5.4 (incl. Vaccines, OTC) 24.5 Efient +4.6 Pralia +4.3 Memary +3.7 Daiichi Sankyo, Inc. (US) 13.4 Negative : Loxonin -8.9

  7. Slide 7: Operating Profit

    Operating Profit Decreased by 21.7 Bn JPY (Increased by 1.8 Bn JPY excl. forex impact and special items) (JPY Bn) FY2015 Results 150.4 Revenue -24.2 incl. forex impact -40.8 Revenue 24.2 Cost of Sales +10.6 Increased in revenue excl. forex impact Cost of Sales 10.6 Impact of price revision in Japan

  8. Slide 8: Special Items

    Special Items (JPY Bn) FY2015 Q3 YTD Results FY2016 Q3 YTD Results YoY Gain on sales of subsidiary -2.4 Cost of Sales ‐ +3.5 Gain on sales of fixed assets -1.1 SG&A Restructuring costs in US 6.1 Restructuring costs 10.6 Expenses +12.7 Gain on sales of fixed assets -8.2 R&D Expenses Restructuring cos

  9. Slide 9: Profit Attributable to Owners of the Company

    Profit Attributable to Owners of the Company Decreased by 22.5 Bn JPY (JPY Bn) FY2015 Results 110.7 Operating Profit 21.7 Financial Income / Expenses -8.4 Financial Income Improvement of forex gains/ losses / Expenses 8.4 FY2015: Expenses relating to the sales of Sun Pharma shares etc. Income Taxes

  10. Slide 10: Major Business Units

    Major Business Units (JPY Bn) FY2015 FY2016 vs. Forecast* Q3 YTD Q3 YTD YoY (%) Results Results Japan 377.5 390.2 +12.8 77.3% Daiichi Sankyo Healthcare 39.9 51.9 +12.0 78.6% Daiichi Sankyo Inc. 145.5 115.8 -29.7 80.4% Olmesartan 88.4 60.9 -27.5 84.6% Welchol 37.7 32.2 -5.5 78.5% Effient 16.4 16.5 +0

  11. Slide 11: Major Products in Japan

    Major Products in Japan (JPY Bn) FY2015 FY2016 vs. Forecast* Q3 YTD Q3 YTD YoY (%) Results Results Nexium ulcer treatment 62.0 67.4 +5.5 81.2% Olmetec antihypertensive agent 60.5 54.1 -6.4 78.4% Alzheimer’s disease Memary treatment 32.7 36.3 +3.7 74.2% Loxonin anti-inflammatory analgesic 38.2 29.3 -

  12. Slide 12: FY2016 Revised Consolidated Forecast

    FY2016 Revised Consolidated Forecast 11

  13. Slide 13: FY2016 Revised Consolidated Forecast

    FY2016 Revised Consolidated Forecast (JPY Bn) FY2016 FY2016 Major factors vs. Forecast Forecast Forecast -Forex impact +13.0 (as of Oct.) (as of Oct.) (as of Jan.) -Japan +6.0 -Overseas +9.0 Revenue 920.0 950.0 +30.0 Major factors Cost of Sales 307.0 318.0 +11.0 -Forex impact +3.0 -Increase by incre

  14. Slide 14: Grow Edoxaban

    Dalichi-Sankyo Grow Edoxaban 13

  15. Slide 15: Edoxaban: Japan

    Edoxaban: Japan The DOAC market in Japan is expanding steadily. The sales market share of Lixiana has reached 14.3% (CY base). (JPY Bn) 165.5 150 23.7 14.3% 129.0 120 12.8 9.9% 88.9 90 1.4 1.6% 60 Lixiana 30 0 CY2014 CY2015 CY2016 Copyright © 2017 QuintilesIMS Calculated based on JPM Sales Data 2014

  16. Slide 16: Edoxaban: Japan market share in new patients

    10 15 20 25 30 35 0 5 (%) Sep-14 Oct-14 Nov-14 Dec-14 Source :Medi-trend Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Edoxaban: Japan Aug-15 Sep-15 Oct-15 in new patients for AF+VTE. Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 As of Nov. 2016, Lixia

  17. Slide 17: Edoxaban: Germany and South Korea

    Edoxaban: Germany and South Korea Steady uptake of sales share after launch (%) (%) Germany South Korea 6 5.5% 12 10.8% 5 10 4 8 3 6 2 4 1 2 0 0 Feb-16 Jan-16 Mar-16 Jun-16 Jan-16 Feb-16 Mar-16 Jun-16 Jul-16 Jul-16 Oct-16 May-16 Aug-16 Sep-16 Oct-16 Nov-15 Dec-15 Apr-16 Nov-16 May-16 Aug-16 Sep-16 A

  18. Slide 18: Maximize Sales Potential of Injectafer

    Maximize Sales Potential of Injectafer 17

  19. Slide 19: Untapped Potential of Injectafer

    Untapped Potential of Injectafer Injectafer* has grown steadily in the US IV Iron market. However there is still potential for further growth. US IV Iron Market (includes dialysis) 800 760.8 700 655.1 28.9% 600 577.5 19.2% 8.8% 500 15.9% 17.3% 16.1% Injectafer $M 400 7.3% 6.3% 5.0% 8.5% 7.6% 6.3% 30

  20. Slide 20: Former Design

    Former Design In IDA* treatment, market beyond Oncologist and Hem/Onc. has not been tapped since LPI focused its limited resources on the area of Oncologist and Hem/Onc. Chronic Women’s IBD/ ND-CKD Heart Oncology Health GI Failure Patients’ Visit to Hospitals / Clinics / Physician Offices OBGYN Card

  21. Slide 21: New Design as of Jan. 2017

    New Design as of Jan. 2017 LPI sales team for Injectafer has become DSI employees. DSI/LPI formed a united sales team for Injectafer to accelerate growth. Chronic Women’s IBD/ ND-CKD Oncology Heart Health GI Failure Patients’ Visit to Hospitals / Clinics / Physician Offices OBGYN Cardiologist Gastro

  22. Slide 22: Additional Effect on DS Group's US Business by United Sales Team

    Additional Effect on DS Group’s US Business by United Sales Team for Injectafer United sales team for Injectafer To accelerate growth beyond oncologist and hem/onc Leverage DSI’s existing sales & marketing infrastructure for Injectafer Establish a foundation for DSI’s oncology business leveraging

  23. Slide 23: Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma

    Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma 22

  24. Slide 24: Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma

    Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma  Kite Pharma, Inc. (Kite)  Located in California, US, Established in 2009, NASDAQ IPO in 2014  One of the leading development companies for engineered T-cell* therapy in oncology * Chimera Antigen Receptor T-cell: CAR-T T-cell R

  25. Slide 25: Chimera Antigen Receptor T-cell: CAR-T

    Chimera Antigen Receptor T-cell: CAR-T From Kite IR material 24

  26. Slide 26: Production timeline of engineered T-cell

    Production timeline of engineered T-cell Employing refined and optimized process, therapeutic T-cell is available within 16-18 days with high probability of production success (97%) * Medical center Cell engineering facility Medical center Selection of patients Quality Preparation Collection of Tran

  27. Slide 27: KTE-C19

    KTE-C19  Development Status Several clinical studies including non-Hodgkin's lymphoma are on-going  US: Breakthrough Therapy Designation(DLBCL1/TFL2/PMBCL3) Rolling BLA submission for refractory aggressive non-Hodgkin lymophoma was initiated in Dec 2016 and will be completed in CY2017 Q1  EU:PRIM

  28. Slide 28: KTE-C19: ZUMA-1 Interim Analysis

    KTE-C19 ZUMA-1 Phase 2 Interim Analysis(ASH 2016)  Chemorefractory patients with DLBCL, TFL, PMBCL  76 % of patients with DLBCL achieved objective response (p < 0.0001) and 47 % complete remissions (CR) at pre-specified interim analysis  Adverse events in patients with a minimum one month follow

  29. Slide 29: ADC franchise enhancement

    ADC franchise enhancement 28

  30. Slide 30: ADC franchise enhancement: U3-1402 HER3-ADC

    ADC franchise enhancement: U3-1402 HER3-ADC Linker & Payload: same as DS-8201 Triggered by binding of Antibody:Patritumab patritumab, 60-80% of HER3 are internalized U3-1402 HER3-ADC Desirable characterization for ADC 29

  31. Slide 31: U3-1402 HER3-ADC: non-clinical xenograft data

    ADC franchise enhancement: U3-1402 HER3-ADC Patient-derived HER3-positive (HER2- 1. HER3 overexpression is negative) Xenograft models reported in breast cancer (BC) and correlated with poor prognosis* - HR+ BC model - - TNBC model -  Unmet Medical Needs for Estimated tumor volume, (mm^3) 2000 BC wi

  32. Slide 32: U3-1402 HER3-ADC: Phase 1/2 study

    ADC franchise enhancement: U3-1402 HER3-ADC  Initiated Phase 1/2 study in Japan  Research participants  HER3-positive advanced/unresectable metastatic breast cancer, treated with standard treatment, or no standard treatment is available  Study design(estimated enrollment: 80)  Dose escalation p

  33. Slide 33: Major R&D milestone events

    Major R&D milestone events Project Indication/Study Event Target Pain/Opioid-induced nausea and vomiting PDUFA date CL-108 (US) Approval Jan. 31, 2017 Denosumab Rheumatoid arthritis (JP) Approval FY2017 CHS-0214 Rheumatoid arthritis (JP) NDA FY2016 (etanercept BS) METIV・HCC Hepatocellular carcinoma

  34. Slide 34: Reference

    Dalichi-Sankyo 33

  35. Slide 35: Major R&D Pipeline

    Major R&D Pipeline As of January 2017 Therapeutic area Phase 1 Phase 2 Phase 3 Application  DS-3032 (US/JP) DS-8895 (JP)  Patritumab (EU)  Tivantinib (US/EU) (MDM2 inhibitor) (Anti-EPHA2 antibody) (U3-1287 / Anti-HER3 antibody) (ARQ 197 / HCC / MET inhibitor)  PLX7486 (US)  DS-8273 (US)  Deno

  36. Slide 36: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: DaiichiSankyoIR@daiichisankyo.co.jp

Daiichi Sankyo Company — FY2016 Q3 Earnings Presentation on 6ix